F-1/A 1 d447751df1a.htm F-1/A F-1/A

As filed with the Securities and Exchange Commission on May 21, 2013

Registration No. 333-188556

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Amendment No. 4

to

FORM F-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Constellium N.V.

(Exact name of Registrant as specified in its charter)

 

 

 

The Netherlands   3341   Not Applicable

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

Tupolevlaan 41-61

1119 NW Schiphol-Rijk

The Netherlands

+31 20 654 97 80

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

Corporation Service Company

80 State Street

Albany, NY 12207-2543

(518) 433-4740

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Andrew J. Nussbaum

Karessa L. Cain

Wachtell, Lipton, Rosen & Katz

51 West 52nd Street

New York, NY 10019

Phone: (212) 403-1000

Fax: (212) 403-2000

 

Keith L. Halverstam

Christopher R. Plaut

Latham & Watkins LLP

885 Third Avenue

New York, NY 10022

Phone: (212) 906-1200

Fax: (212) 751-4864

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.    ¨

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    ¨

 

 

 

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.

 

 

 


EXPLANATORY NOTE

This Amendment No. 4 is being filed solely for the purposes of amending Item 8 of Part II of the Registration Statement and to file certain exhibits indicated in such Item. Accordingly, this Amendment No. 4 consists only of the facing page, this explanatory note and Part II to the Registration Statement.


PART II

INFORMATION NOT REQUIRED IN THE PROSPECTUS

 

Item 8. Exhibits

(a) See Exhibit Index beginning on page II-4 of this registration statement.

The agreements included as exhibits to this registration statement contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties were made for the benefit of the other parties to the applicable agreement and (i) were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) may have been qualified in such agreement by disclosures that were made to the other party in connection with the negotiation of the applicable agreement; (iii) may apply contract standards of “materiality” that are different from “materiality” under the applicable securities laws; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement.

We acknowledge that, notwithstanding the inclusion of the foregoing cautionary statements, we are responsible for considering whether additional specific disclosures of material information regarding material contractual provisions are required to make the statements in this registration statement not misleading.

(b) Financial Statement Schedules

All schedules have been omitted since they are not required or are not applicable or the required information is shown in the financial statements or related notes.

 

II-1


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this Amendment No. 4 to its registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on May 21, 2013.

 

Constellium N.V.
By:  

/s/    Pierre Vareille

 

Name:

Title:

 

Pierre Vareille

Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been executed as a deed by the following persons on May 21, 2013 in the capacities indicated:

 

Name

 

Title

/s/    Pierre Vareille

Pierre Vareille

  Chief Executive Officer (Principal Executive Officer)

/s/    Didier Fontaine

Didier Fontaine

 

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

  *

Richard B. Evans

  Chairman

/s/    Pierre Vareille

Pierre Vareille

  Director

  *

Gareth N. Turner

  Director

  *

Guy Maugis

  Director

   

Werner P. Paschke

  Director

   

Pieter Oosthoek

  Director

  *

Matthew H. Nord

  Director

  *

Bret Clayton

  Director

 

Philippe Guillemot

  Director

 

*By:  

/s/ Pierre Vareille

 

Pierre Vareille

Attorney-in-fact

 

Constellium Holdings I, LLC

/s/ Didier Fontaine

  Authorized U.S. Representative

Didier Fontaine

President

 

 

II-2


EXHIBIT INDEX

The following documents are filed as part of this registration statement:

 

  1.1    Form of Underwriting Agreement†
  3.1    Amended and Restated Articles of Association of Constellium N.V.†
  3.2    Deed of Conversion-Constellium N.V.**
  4.1    Partnership Agreement of Omega Management GmbH & Co. KG as amended and restated as of May 21, 2013†
  4.2    Second Amendment to Credit Agreement, dated as of March 25, 2013, among Constellium N.V., as the Dutch Borrower, Constellium France S.A.S., as the French Borrower, the new Term Lenders party thereto, Deutsche Bank Trust Company Americas, as the Existing Administrative Agent, and Deutsche Bank AG New York Branch, as the successor Administrative Agent†
  4.3    ABL Credit Agreement, dated as of May 25, 2012, among Constellium Holdco II B.V., Constellium U.S. Holdings I, LLC, Constellium Rolled Products Ravenswood, LLC, as borrower, the lenders from time to time party hereto, and Deutsche Bank Trust Company Americas, as Administrative Agent and Collateral Agent†
  4.4    Second Amendment to Credit Agreement, dated as of March 25, 2013, among Constellium Rolled Products Ravenswood, LLC, as borrower, and Deutsche Bank Trust Company Americas, as Administrative Agent and Collateral Agent†
  5.1    Opinion of Stibbe, Dutch counsel to Constellium N.V., as to the validity of the ordinary shares being issued**
10.1    Form of Amended and Restated Shareholders Agreement, among Constellium N.V. and the other signatories thereto†
10.2    2012 Executive Performance Award Plan†
10.3    2012 Long-Term Incentive (Cash) Plan†
10.4    Employment Letter by and between Constellium Switzerland AG and Pierre Vareille, dated August 30, 2012†
10.5    Employment Letter by and between Constellium France Holdco SAS and Didier Fontaine, dated May 11, 2012†
10.6    Severance Agreement between Constellium Switzerland AG. Zurich and Arnaud de Weert, dated March 21, 2012†
10.7    Factoring Agreement between Alcan Rhenalu S.A.S. as French Seller, Alcan Aerospace S.A.S. as French Seller, Alcan Softal S.A.S. as French Seller, Alcan France Extrusions S.A.S. as French Seller, Alcan Aviatube S.A.S. as French Seller, Omega Holdco II B.V. as Parent Company, Engineered Products Switzerland A.G. as Sellers’ Agent and GE Factofrance S.N.C. as Factor, dated January 4, 2011, as amended as of May 25, 2012†
10.8    Factoring Agreement between GE Capital Bank AG and Alcan Aluminium Valais S.A., dated December 16, 2010†
10.9    Country Specific Amendment Agreement (Switzerland) to the Factoring Agreement between GE Capital Bank AG and Alcan Aluminium Valais S.A., dated December 16, 2010†
10.10    Factoring Agreement between GE Capital Bank AG and Alcan Aluminium-Presswerke GmbH, dated December 16, 2010†
10.11    Factoring Agreement between GE Capital Bank AG and Alcan Singen GmbH, dated December 16, 2010†

 

II-3


10.12    Metal Supply Agreement between Engineered Products Switzerland AG and Rio Tinto Alcan Inc. for the supply of sheet ingot in Europe, dated January 4, 2011+†
10.13    Form of Constellium N.V. 2013 Equity Incentive Plan†
21.1    List of subsidiaries†
23.1    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm†
23.2    Consent of PricewaterhouseCoopers Audit S.A., Independent Registered Public Accounting Firm†
23.3    Form of Consent of Stibbe (included in Exhibit 5.1)**
24.1    Powers of attorney (included on signature page to the registration statement)†
99.1    Consent of Philippe Guillemot to be named as a director†
99.2    Consent of Werner P. Paschke to be named as a director†
99.3    Consent of Pieter Oosthoek to be named as a director†

 

* To be filed by amendment.
Previously filed.
** Filed herein.
+ Application has been made to the Securities and Exchange Commission for confidential treatment of certain provisions of this exhibit. Omitted material for which confidential treatment has been requested has been filed separately with the Securities and Exchange Commission.

 

II-4